On Tuesday, the share price of the company rose by 8.5% to its new 52-week high of ₹1,424.65 per share from its previous close of ₹1312.60 after the company announced its financial result and investor presentation for the December quarter.
In their exchange filing, Cipla Ltd announced their financial and investor presentation. Their net revenue increased by 13% YoY from ₹5,810 to ₹6,604, and in QoQ, net revenue decreased by 1.1% from ₹6,678 to its current level.
The company’s net profit increased by 32% YoY from ₹808 to ₹1,068, and in QoQ, their net profit rose by 7.5% from ₹1,155 to its current level.
Furthermore, according to their key highlights, the company’s global revenue increased by 14% YoY, EBITDA margin increased by 24% YoY, the highest ever in a quarterly, and R&D investments increased by 10% YoY.
In addition, their business performance in One-India increased by 12% year on year, in North America by 18% year on year, and in South Africa by 15%.
The company has a low price-to-earnings ratio of 31 compared to its peers, it also has a low debt-to-equity ratio of 0.02, with a return on equity of 12.8%, a return on capital employed of 17.75, and a net profit margin of 12%.
Cipla Ltd is a large cap with a market capitalization of ₹1,14,420 crores, the share price of the company rose by 35% in the last six months and 33% in the last year.
Promoters of the company rose by 34%, the general public holds 19%, the foreign institutional investor holds 25% and domestic institutional investors hold 22% of the company.
Cipla Limited is an Indian multinational pharmaceutical corporation headquartered in Mumbai. Cipla’s primary focus is on developing medicines to treat respiratory diseases, cardiovascular disease, arthritis, diabetes, depression, and a wide range of other medical conditions.
Written by Sriram KV
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
